Post-HSCT Wearable Monitoring

A consumer ring detected a JAK inhibitor response in 8 days.

11 statistical reports. 105,000+ biometric readings. One patient, one Oura Ring Gen 4, zero clinical infrastructure.

Jan 4 – Mar 23, 2026 79 days modeled Ruxolitinib start: Mar 16
Temp Deviation
−0.24 °C shift
p = 0.008 · 99.2% posterior probability
Cardiac Reserve
+1.07 SD shift
p = 0.040 · Kalman filter
Sleep Quality
+0.73 SD shift
p < 0.001 · Mann-Whitney
Autonomic Tone
+0.47 SD shift
p = 0.24 · not significant

Before vs. After Ruxolitinib (March 16)

Metric Pre (71 days) Post (8 days) Change Direction
Resting HR 85.1 bpm 81.8 bpm −3.3 bpm ↓ Improved
HRV (RMSSD) 9.1 ms 10.1 ms +1.0 ms (+11%) ↑ Improved
Temp deviation +0.08 °C −0.16 °C −0.24 °C ↓ Improved
Sleep quality −0.14 SD +0.37 SD +0.51 SD ↑ Improved
Sleep efficiency ~73% ~79% +6 pp ↑ Improved
Confound: HEV diagnosed March 18. Drug and viral effects cannot be fully separated at N=8 post-intervention days.

Family Genetic Control

Enrolled Data collection in progress

Mother (61F) enrolled with Oura Ring. ~50% shared genome. Same pipeline, no disease. Separates inherited baseline from disease signal.

30+ nights targeted. Between-subjects comparison will quantify how much of the autonomic signature is inherited vs. disease-driven.

Read roadmap →
About

Open-source platform built by a single post-HSCT patient using Oura Ring Gen 4 data. MIT licensed through The Educational Equality Institute.

What Happens Next

Phase Target Description Status
Now Day 8 Ruxolitinib response — current analysis window Active
Day 28 ~Apr 13 Statistical significance threshold — if signals persist Pending
Family control Day 1 Mother enrolled. ~50% shared genome, same pipeline Enrolled
Multi-user TBD GvHD vs stroke vs healthy — between-subjects CausalImpact Planned
Read full roadmap →

Methodology

All analyses are reproducible Python scripts running against a single SQLite database. The full pipeline runs in under 10 minutes on commodity hardware.

View source on GitHub ↗